| Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy W Ma, BM Gilligan, J Yuan, T Li Journal of hematology & oncology 9, 1-21, 2016 | 336 | 2016 |
| Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report H Li, W Ma, KY Yoneda, EH Moore, Y Zhang, LLQ Pu, GM Frampton, ... Journal of hematology & oncology 10 (1), 64, 2017 | 33 | 2017 |
| High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer W Xiao, W Ma, S Wei, Q Li, R Liu, RP Carney, K Yang, J Lee, A Nyugen, ... Journal of hematology & oncology 12, 1-18, 2019 | 32 | 2019 |
| Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors C Zhou, Z Yuan, W Ma, L Qi, A Mahavongtrakul, Y Li, H Li, J Gong, ... Journal of hematology & oncology 11, 1-13, 2018 | 27 | 2018 |
| Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors J Gong, JP Gregg, W Ma, K Yoneda, EH Moore, ME Daly, Y Zhang, ... Journal of the National Comprehensive Cancer Network 17 (4), 297-301, 2019 | 21 | 2019 |
| Reduced expression of Slit2 in renal cell carcinoma WJ Ma, Y Zhou, D Lu, D Dong, XJ Tian, J Wen, J Zhang Medical Oncology 31, 1-7, 2014 | 21 | 2014 |
| Cancer neoantigens as potential targets for immunotherapy W Ma, B Pham, T Li Clinical & experimental metastasis 39 (1), 51-60, 2022 | 19 | 2022 |
| Translational biomarkers and rationale strategies to overcome resistance to immune checkpoint inhibitors in solid tumors JA Chen, W Ma, J Yuan, T Li Tumor Microenvironment, 251-279, 2020 | 16 | 2020 |
| High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer Q Li, W Ma, S Chen, EC Tian, S Wei, RR Fan, T Wang, C Zhou, T Li Translational lung cancer research 9 (4), 1361, 2020 | 14 | 2020 |
| Targeting HER2 genomic alterations in non-small cell lung cancer J Zeng, W Ma, RB Young, T Li Journal of the National Cancer Center 1 (2), 58-73, 2021 | 13 | 2021 |
| Giant magnetoresistive nanosensor analysis of circulating tumor dna epidermal growth factor receptor mutations for diagnosis and therapy response monitoring JC Nesvet, KA Antilla, DS Pancirer, AX Lozano, JS Preiss, W Ma, A Fu, ... Clinical Chemistry 67 (3), 534-542, 2021 | 11 | 2021 |
| Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC T Li, W Ma, EC Tian Chin Clin Oncol 8 (S1), S4, 2019 | 8 | 2019 |
| Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer Q Li, W Ma, T Li Journal of Thoracic Disease 10 (Suppl 26), S3186, 2018 | 6 | 2018 |
| Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M … W Ma, J Gong, J Shan, D Lewis, W Xiao, EH Moore, Y Zhang, J Hung, ... JCO Precision Oncology 2, 1-7, 2018 | 5 | 2018 |
| Emerging EML4-ALK variant 5 as a concurrent resistance mechanism to osimertinib in a patient with EGFR E19del/T790M NSCLC Y Yan, G Jiang, W Ma, T Li, L Wang Clinical Lung Cancer 21 (6), 562-567, 2020 | 4 | 2020 |
| JCES01. 10 Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer Y Zhao, J Gong, W Ma, K Banks, H Wen, EH Moore, R Lanman, T Li Journal of Thoracic Oncology 12 (1), S234, 2017 | 3 | 2017 |
| Increasing cure rates of solid tumors by immune checkpoint inhibitors W Ma, R Xue, Z Zhu, H Farrukh, W Song, T Li, L Zheng, C Pan Experimental Hematology & Oncology 12 (1), 1-19, 2023 | 2 | 2023 |
| Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC W Ma, J Zeng, S Chen, Y Lyu, KA Toomey, CT Phan, KY Yoneda, T Li Biomarker research 9 (1), 1-20, 2021 | 2 | 2021 |
| Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory … H Zhao, W Ma, RC Fragoso, GR Harsh IV, A Ashok, T Li Journal of the National Cancer Center 1 (3), 115-121, 2021 | 2 | 2021 |
| Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives LA Godoy, J Chen, W Ma, J Lally, KA Toomey, P Rajappa, R Sheridan, ... Biomarker Research 11 (1), 1-29, 2023 | 1 | 2023 |
Jianda Yuan MD. Ph.D.Memorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
